Benda Pharma 
Welcome,         Profile    Billing    Logout  
 1 Product   58 Diseases  1 Product   4 Trials   31 News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gendicine (rAd-p53 Gene Therapy) / Benda Pharma
ChiCTR-TRC-08000094: Gendicine intratumoral injection combined with radiotherapy for advanced nasopharyngeal carcinoma (phase IV)

Completed
4
400
 
The conventional fractionation 2Gy/day, five fract ;The conventional fractionation 2Gy/day, five fract
Beijing hospital; The Ministry of Science and Technology of the People’s Republic of China, China Shenzhen SiBiono GeneTech Co. Ltd
advanced nasopharyngeal carcinoma
 
 
ChiCTR-TRC-08000092: Gendicine intratumoral injection combined with radiotherapy for advanced nasopharyngeal carcinoma

Completed
1/2
80
 
In the GTRT group, Gendicine 1*10^12 virus particle ;In the GTRT group, Gendicine 1*10^12 virus particle
Beijing Cancer Hospital; Level of the institution：, China Shenzhen SiBiono GeneTech Co. Ltd
Advanced nasopharyngeal carcinoma
 
 
ChiCTR-TRC-08000091: Gendicine intratumoral injection combined with radiotherapy for advanced cervical carcinoma

Completed
1
240
 
the conventional fractionation 2Gy/day, five fractions a week, with a total dose of 70-80Gy was given to the primary tumor ;In the GTRT group, Gendicine 1*10^12 virus particle (vp) was intratumorally injected once a week for six weeks and concurrently irradiation was given. the conventional fractionation 2Gy/day, five fractions a week, with a total dose of 70-80Gy was given to the primary tumor
Beijing Cancer Hospital; Level of the institution：, The Ministry of Science and Technique of China (973 project)
Advanced cervical carcinoma
 
 

Download Options